Press Releases

Kunle Odunsi, MD, PhD, FRCOG, FACOG
News

Roswell Park’s Dr. Kunle Odunsi Elected to the National Academy of Medicine

Kunle Odunsi, MD, PhD, Deputy Director of Roswell Park Comprehensive Cancer Center, has been elected to the National Academy of Medicine — a distinguished lifetime designation that is considered one of the highest honors in health and medicine. The election of new members recognized for their outstanding professional achievements and commitment to service was announced today at the Academy’s annual meeting in Washington, D.C.
News

Compound Derived From Chinese Tree Bark Shows Promise as Treatment for Pancreatic Cancer

A new derivative of a compound found in the bark of a rare Chinese tree has powerful anticancer properties and a low toxicity profile, according to researchers at Roswell Park Comprehensive Cancer Center. Results of their study of the effects of the compound F118 in pancreatic cancer were published today in the Journal of Experimental & Clinical Cancer Research.
Grace Dy, MD
News

Roswell Park Lung Cancer Expert Shares Initial Findings From First North American Study of CIMAvax

Initial results from the first North American clinical trial of CIMAvax-EGF show that this Cuban-developed immunotherapy is safe, well tolerated and worthy of further study. Principal Investigator Grace Dy, MD, of Roswell Park Comprehensive Cancer Center shared the findings yesterday at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.
News

Governor Cuomo Announces First-Ever Biotech Venture Between U.S. and Cuba to Research and Develop New Cancer Treatments

Governor Andrew M. Cuomo today announced Buffalo-based Roswell Park Comprehensive Cancer Center has formed Innovative Immunotherapy Alliance S.A., the first-ever biotech venture between the U.S. and Cuba. The announcement marks a significant milestone of progress following Governor Cuomo’s landmark trade mission to Cuba in April 2015, where he facilitated this historic partnership between Roswell Park and the Center for Molecular Immunology. This historic step will advance the research and development of new cancer medicines that may prolong and enhance survival for thousands of U.S. patients.
Dr. Marc Ernstoff
News

New Immunotherapy Approach Found in “Superagonist” Interleukin-15 Complex

A recent development shows that the immune response to cancer can be further enhanced using cytokines, small proteins that act as chemical messengers transporting information between different types of immune cells. A clinical trial led by Marc Ernstoff, MD, the Katherine Anne Gioia Chair of Medicine at Roswell Park Comprehensive Cancer Center, found that a drug complex containing one of these cytokines, interleukin-15 (IL-15), is both safe and well tolerated in patients with advanced solid tumors. The findings have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).